Entero Healthcare Solutions Limited announced its audited financial results for the quarter and year ended March 31, 2026, reporting a robust annual revenue of Rs. 3,482.41 million on a standalone basis and Rs. 65,912.12 million consolidated. Alongside strong financial performance, the Board approved strategic leadership re-appointments, the upcoming 8th Annual General Meeting, and the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals to bolster its distribution network.
Financial Performance Overview
For the financial year ended March 31, 2026, the company achieved consolidated revenue from operations of Rs. 65,912.12 million, compared to Rs. 50,957.80 million in the previous year. The consolidated profit for the year stood at Rs. 1,458.40 million, marking a significant growth trajectory. On a standalone basis, the company reported an annual revenue of Rs. 3,482.41 million with a net profit of Rs. 268.75 million.
Strategic Acquisitions
The company continues to expand its footprint through the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals. This strategic move, executed via a business transfer agreement through its subsidiary, Sai Pharma Distributors Private Limited, is designed to enhance the company’s presence in the wholesale distribution of pharmaceuticals and surgical products. The acquisition is expected to be completed by December 31, 2026.
Board and Governance Updates
The Board of Directors has approved the re-appointment of several key Non-Executive Independent Directors, including Mr. Sujesh Vasudevan, Mr. Rajesh Shashikant Dalal, and Ms. Sandhya Gadkari Sharma, for a second term of five years effective August 25, 2026. Additionally, the company confirmed that its 8th Annual General Meeting will be held on August 19, 2026, via video conferencing.
Employee Stock Option Plans
In a move to incentivize talent, the company has allotted 7,240 equity shares to eligible employees following the exercise of options under the Entero Employee Stock Option Plan 2023. Furthermore, the Board has noted the grant of 7,300 fresh stock options, reflecting a continued commitment to employee retention and long-term value creation.
Source: BSE
